Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Eisai

Founders Haruo Naito Yasushi Okada

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 15
Average round size
info
The average size of a deal this fund participated in
$21M
Portfolio companies 12
Rounds per year 0.18
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.13
Exits 3
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Life Science
  • Therapeutics

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Eisai:
Typical Co-investors
Eisai is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Eisai:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AB Capital Group -
Amatil X Ventures Australia, New South Wales, North Sydney
Asia PropTech China, Hong Kong, Hong Kong Island
Bio-sight Capital Ibaraki, Japan, Osaka Prefecture
Chengdu Zhengjian Chengdu, China, Sichuan
Desai Capital Management -
Growth Catalyst Partners Chicago, Illinois, United States
Howell Capital California, San Francisco, United States
IBT Management Corporation Taipei, Taiwan
LearnStart New York, New York, United States
Mavrik -
Script Capital France, Ile-de-France, Paris
Sevenwoods Investment Chiba Prefecture, Japan, Tateyama
Shanghai-Israel Investment Fund -
Sydes -
The Home Depot Atlanta, Georgia, United States
Tolero Ventures California, Los Angeles, United States
U.S. Bank Trust National Association Delaware, United States, Wilmington
Withfounders Italy, Lombardia, Milano

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Casma Therapeutics

Biotechnology
Health Care
Therapeutics
$46M15 Nov 2022 Cambridge, Massachusetts, United States

Ractigen Therapeutics

Health Care
Pharmaceutical
$30M27 Jan 2022 Nantong, Jiangsu, China

PRISM BioLab

Biopharma
Biotechnology
Pharmaceutical
Therapeutics
$15M12 Oct 2021 Fujisawa, Kanagawa Prefecture, Japan

Neuroglee Therapeutics

Biotechnology
Life Science
$10M09 Sep 2021 Singapore, Central Region, Singapore

ŌURA

Health Care
Mobile Apps
Wearables
Wellness
$100M04 May 2021 Oulu, Oulu, Finland

Allm

Health Care
Information and Communications Technology (ICT)
Information Technology
Medical
$50M05 Apr 2021 Chiyoda, Japan

Neuroglee Therapeutics

Biotechnology
Life Science
$2M03 Dec 2020 Singapore, Central Region, Singapore

Artificial Intelligence
Bioinformatics
Biopharma
Clinical Trials
Life Science
Machine Learning
Software
$3M05 Nov 2020 San Francisco, California, United States

Darmiyan

Artificial Intelligence
Biotechnology
Enterprise Software
Health Care
Health Diagnostics
Machine Learning
Medical
Software
$6M10 Apr 2020 San Francisco, California, United States
News
Digital therapeutics startup Neuroglee raises $10M to help people with neurodegenerative conditions

– Neuroglee Therapeutics, a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10m Series A led by Openspace Ventures and EDBI.
– The funding will be used to launch virtual neurology clinics and to support Neuroglee’s move to Boston.
– Other participants included Ramen Singh, the former chief executive officer of Mundipharma; Biofourmis co-founders Kuldeep Singh Rajput and Wendou Liu; and Eisai, the Japanese pharmaceutical that led Neuroglee’s last round last year.
– Neuroglee’s adaptive learning tech uses machine learning and biomarkers related to cognitive function, mood and behavior to automatically personalize therapy plans for each patient, who access the software through a smartphone or tablet.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Eisai?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 15
Average round size 21M
Rounds per year 0.18
Peak activity year 2021
Lead investments 2
Follow on index 0.13
Exits 3
Group Appearance index 0.67

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Casma Therapeutics

Biotechnology
Health Care
Therapeutics
$46M15 Nov 2022 Cambridge, Massachusetts, United States

Ractigen Therapeutics

Health Care
Pharmaceutical
$30M27 Jan 2022 Nantong, Jiangsu, China

PRISM BioLab

Biopharma
Biotechnology
Pharmaceutical
Therapeutics
$15M12 Oct 2021 Fujisawa, Kanagawa Prefecture, Japan

Neuroglee Therapeutics

Biotechnology
Life Science
$10M09 Sep 2021 Singapore, Central Region, Singapore

ŌURA

Health Care
Mobile Apps
Wearables
Wellness
$100M04 May 2021 Oulu, Oulu, Finland

Allm

Health Care
Information and Communications Technology (ICT)
Information Technology
Medical
$50M05 Apr 2021 Chiyoda, Japan

Neuroglee Therapeutics

Biotechnology
Life Science
$2M03 Dec 2020 Singapore, Central Region, Singapore

Artificial Intelligence
Bioinformatics
Biopharma
Clinical Trials
Life Science
Machine Learning
Software
$3M05 Nov 2020 San Francisco, California, United States

Darmiyan

Artificial Intelligence
Biotechnology
Enterprise Software
Health Care
Health Diagnostics
Machine Learning
Medical
Software
$6M10 Apr 2020 San Francisco, California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: